. 2021 May;9(10):867. doi: 10.21037/atm-21-1606

Table 3. Pharmacokinetic parameters of [¹⁴C]almonertinib and its metabolites in mixed plasma of participants.

Metabolite No.	T_1/2 (h)	t_max (h)	C_max (ng Eq/g)	AUC_{0–48 h} (h ng Eq/g)	MRT_{0–48 h} (h)	%AUC^a (%)
Total plasma	105	4	464	15,513	22.9	100.00
[¹⁴C]almonertinib	167	4	286	10,854	23.7	69.97
M440	1.95*	4	101	788	10.7	5.08

The half-life (T_1/2) of M440 was calculated using the data at 4, 6, and 10 h. %AUC = the plasma exposure of the parent drug or metabolite within 0–48 h (AUC_{0-48 h}) (ng×h/mL) ÷ the total plasma exposure within 0–48 h (AUC_{0-48 h}) (ng×h/mL). MRT, mean residence time.

Table 3. Pharmacokinetic parameters of [14C]almonertinib and its metabolites in mixed plasma of participants.

Table 3. Pharmacokinetic parameters of [¹⁴C]almonertinib and its metabolites in mixed plasma of participants.